Table 2.

Prevalence and extenta of inflammation assessed in benign prostate tissue from biopsy cores, prostate cancer cases overall and by grade and controlsb, placebo arm, and the PCPT

Prostate cancer cases
ControlsTotalLow-gradeHigh-grade
N2091919794
At least one biopsy core with inflammation (%)c78.286.2e84.088.4e
Mean of the percentage of biopsy cores with inflammationc52.158.756.161.4e
Mean of the mean percentage of tissue area with inflammationd
 Overall11.510.910.810.9
 In men with at least one biopsy core with inflammation14.712.612.812.3
  • aFrom generalized linear models (linear for adjusted proportions and means, logistic for P values) adjusting for baseline age, family history of prostate cancer, and race.

  • bCases and controls were frequency matched on baseline age and family history of prostate cancer. All non-White controls were sampled. Cases were sampled from the placebo arm of the trial so that half were high grade (Gleason sum ≥7) and half were low grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal DRE (for-cause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls were sampled from men who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol.

  • cFor each man, the denominator is total number of biopsy cores evaluated.

  • dFor each man, the denominator is total benign tissue area across all biopsy cores evaluated on each of the slides of the man.

  • eP < 0.05 compared with controls.